Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of “Moderate Buy” from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $29.20.

Several research firms have commented on KURA. Wedbush restated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Friday, August 9th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the stock from $26.00 to $19.00 in a report on Monday. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Monday, September 9th.

Institutional Investors Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC acquired a new stake in Kura Oncology during the first quarter worth approximately $507,000. Hennion & Walsh Asset Management Inc. lifted its position in Kura Oncology by 42.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock valued at $3,875,000 after acquiring an additional 54,031 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after acquiring an additional 577,732 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Finally, Sofinnova Investments Inc. increased its position in shares of Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after purchasing an additional 323,303 shares in the last quarter.

Kura Oncology Price Performance

KURA opened at $18.21 on Wednesday. The stock’s 50-day moving average price is $19.58 and its 200 day moving average price is $20.27. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -8.39 and a beta of 0.84. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same quarter last year, the firm posted ($0.53) EPS. The firm’s quarterly revenue was up .0% on a year-over-year basis. As a group, sell-side analysts expect that Kura Oncology will post -2.45 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.